← Back to Treatments
🏅 FDA Orphan Designation

OPDIVO� and YERVOY�

nivolumab and ipilimumab

Manufacturer: Bristol-Myers Squibb Company

Indicated for:
Pleural mesotheliomaOrphanMalignant peritoneal mesothelioma

FDA-Approved Indications (2)

Pleural mesotheliomaOrphan Designation

YERVOY� (ipilimumab), in combination with nivolumab, is indicated for the first-line treatment of adult patients with unresectable malignant pleural mesothelioma.

YERVOY (ipilimumab), in combination with nivolumab, is indicated for the first-line treatment of adult patients with unresectable malignant pleural mesothelioma

Population: adults

Indications & Usage

YERVOY� (ipilimumab), in combination with nivolumab, is indicated for the first-line treatment of adult patients with unresectable malignant pleural mesothelioma. ||| OPDIVO, in combination with ipilimumab, is indicated for the first-line treatment of adult patients with unresectable malignant pleural mesothelioma.

💙 Support Programs

View all →
OPDIVO� and YERVOY�
Bristol-Myers Squibb Company
Apply ↗

Where shown, WAC (Wholesale Acquisition Cost) is an estimate only — your actual cost depends on your insurance plan. Always verify pricing with your pharmacy or insurer.

Medical disclaimer: This information is for educational purposes only. Always consult a qualified healthcare provider before making treatment decisions. Data sourced from FDA and current as of our last update.